NCT04565145View on ClinicalTrials.gov

Biomarker Changes and Anxiolytic Effects-Phase 2

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

April 5, 2021

Primary Completion Date

July 1, 2023

Study Completion Date

July 1, 2023

Conditions
Pharmacokinetics
Interventions
DRUG

Kava Dietary Supplement

Participants will be given three 75mg kava capsules per day for one week

DRUG

Placebo

Participants will be given three placebo capsules per day for one week

Trial Locations (1)

32610

UF CTSI Clinical Research Center, Gainesville

All Listed Sponsors
collaborator

Thorne HealthTech, Inc

INDUSTRY

collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

lead

University of Florida

OTHER

NCT04565145 - Biomarker Changes and Anxiolytic Effects-Phase 2 | Biotech Hunter | Biotech Hunter